Company
Every investor coverage indicates participated in a round Viral Vector Manufacturing Facility raised.
Companies Viral Vector Manufacturing Facility acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Viral Vector Manufacturing Facility. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A profile of Chimeric Therapeutics and CEO Rebecca McQualter covering its CAR T cancer therapy, clinical progress, manufacturing partnerships, FDA designations, and path to Phase 2 trials by mid-2026.
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Cut Through Venture·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·Forbes Australia·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com·Forbes Australia